In a constantly evolving sector, the pharmaceutical industry faces a core challenge on two levels: innovating at an ever-faster pace, while attracting and retaining the talent needed to help drive this transformation. To better understand these challenges, we met with Katéri Cuvillier, Group Director of Talent Acquisition at Servier.
Hello Katéri. Why is talent attraction a strategic priority for the pharmaceutical industry today, and specifically for Servier?
Talent acquisition is a major strategic driver for the pharmaceutical industry because innovation, the digital transformation, market globalization and the continuously changing regulatory requirements all call for increasingly specialized, agile and scarce skills. The development of new treatments, particularly in complex therapeutic areas, relies on the ability to mobilize the right expertise at the right time. At Servier, we focus our R&D efforts on rare diseases, particularly in oncology and neurology. To meet patient needs, our teams capitalize on precision medicine.
This approach requires us to attract professionals who are at the cutting edge of science and technology, and who are also deeply resilient and committed to meeting the challenges involved with pathologies that are still relatively unexplored.
Moreover, Servier is currently rolling out a major transformation looking ahead to 2030, around a very strong ambition. In this dynamic context, talent acquisition is essential in order to sustain this transformation over the long term. It is the expertise of our employees that will enable the Group to achieve its ambitions and sustainably strengthen its impact on serving patients.
Lastly, the global competition for qualified talent is intensifying, especially in research and development, data, artificial intelligence, supply chain and manufacturing. In this attractive but competitive market, recruiting and retaining the best profiles is more crucial than ever in order to stay at the forefront of innovation, accelerate drug development cycles and, ultimately, better meet patients’ needs.
Which profiles are most sought after in the pharmaceutical industry today, and why?
Today, the pharmaceutical industry is actively seeking profiles that are specialized in regulatory affairs, clinical development, quality, supply chain and biomanufacturing. This demand reflects a reinforced regulatory framework, the growth in clinical trials and the increasing complexity of biotherapies, which require rigorous and secure processes.
Alongside this, faced with the sector’s growing digitalization, expertise in data and AI is becoming essential. However, only 8% of pharmaceutical companies consider they have fully integrated this technology into their processes1. So, there is a challenge on two levels: to recruit qualified talent in these emerging fields and to support the upskilling of internal teams.
What are the current and future challenges for talent acquisition in our industry, and for Servier in particular?
Attracting, integrating and developing talent is a multidimensional challenge. Several dynamics are making this equation more complex in the pharmaceutical sector:
For the future, we must anticipate today the rapid evolution of skills, with the growing integration of AI, digital health and personalized medicine. These transformations require continuous upskilling and the proactive monitoring of tomorrow’s profiles. To prepare for this, at Servier we closely monitor changes in the market through our Talent Acquisition team and our external partners.
What differentiating strengths does Servier have to attract talent, and what strategy is the Group implementing to address this challenge?
Servier has chosen independence by deciding to be governed by a foundation. This unique structure fundamentally sets us apart from other pharmaceutical companies, as patients are the ultimate beneficiaries of our actions. This employer value proposition is a factor in attracting talented people, at a time when 20% of young professionals say that they prioritize a meaningful company culture2.
Another differentiating factor is our positioning as a mid-size pharmaceutical company. This mid-size status gives us valuable agility compared with the industry giants. Our human scale also enables easier access to top management. For future talent, this is an opportunity to grow in an environment that encourages collaboration and knowledge sharing at all levels.
We also place a strong emphasis on internal mobility. This enables each individual to pursue a dynamic, evolving career path and discover new professional horizons within the Group.
Lastly, 96% of the people surveyed say that they want their company to commit to a sustainable development program3. In terms of CSR, Servier has launched a range of initiatives focused on workplace safety and well-being, diversity and inclusion, as well as actions to improve water and energy management and, more widely, to reduce environmental impacts throughout the value chain. These commitments represent an additional asset for attracting talented people who are looking for impact and authenticity.
[1] L’automatisation dans l’industrie pharmaceutique connaît un nouvel élan, PR Newswire, 9 mai 2024.
https://www.prnewswire.com/news-releases/lautomatisation-dans-lindustrie-pharmaceutique-connait-un-nouvel-elan–le-rapport-denquete-2024-sur-lindustrie-darisglobal-met-en-evidence-lessor-des-processus-de-securite-et-de-reglementation-alimentes-par-lia-302141483.html
[2] 2024 Gen Z and Millennial Survey, Living and working with purpose in a transforming world, Deloitte, mai 2024.
https://www.deloitte.com/global/en/issues/work/genz-millennial-survey.html
[3] https://www.franceinfo.fr/replay-radio/c-est-mon-boulot/la-crise-sanitaire-a-durablement-change-notre-relation-avec-notre-entreprise_5100658.html